FGFR1 and neoplasm: Since our in-vitro data suggested adding HS5-CM to MCL cells up-regulated FGFR1, we questioned a) whether stroma can promote MCL tumor progression in-vivo and b) if treatment with erdafitinib can abrogate stromal-mediated tumor progression in-vivo.